| [1] |
Beccuti G, Guaraldi F, Natta G, et al. Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study[J]. J Endocrinol Invest,2020. doi: 10.1007/s40618-020-01478-0.
|
| [2] |
Moore TJ, Glenmullen J, Mattison DR. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs[J]. JAMA Intern Med,2014,174:1930-1933.
|
| [3] |
Davie M. Pathological gambling associated with cabergol-ine therapy in a patient with a pituitary prolactinoma[J]. J Neuropsychiatry Clin Neurosci. Fall, 2007,19:473-474.
|
| [4] |
Hinojosa-Amaya JM, Johnson N, González-Torres C, et al. Depression and impulsivity self-assessment tools to identify dopamine agonist side effects in patients with pituitary adenomas[J]. Front Endocrinol (Lausanne),2020,11:579606. doi: 10.3389/fendo.2020.579606.
|
| [5] |
Lin YP, Liang HY, Chen YS, et al. Objective assessment of impulse control disorder in patients with Parkinson's disease using a low-cost LEGO-like EEG headset: a feasibility study[J]. J Neuroeng Rehabil,2021,18:109. doi: 10.1186/s12984-021-00897-1.
|
| [6] |
Drew DS, Muhammed K, Baig F, et al. Dopamine and reward hypersensitivity in Parkinson's disease with impulse control disorder[J]. Brain,2020,143:2502-2518.
|
| [7] |
Klein MO, Battagello DS, Cardoso AR, et al. Dopamine: functions, signaling, and association with neurological diseases[J]. Cell Mol Neurobiol,2019,39:31-59.
|
| [8] |
Celik E, Ozkaya HM, Poyraz BC, et al. Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up[J]. Endocrine,2018,62:692-700.
|
| [9] |
Dogansen SC, Cikrikcili U, Oruk G, et al. Dopamine agonist-induced impulse control disorders in patients with prolactinoma: a cross-sectional multicenter study[J]. J Clin Endocrinol Metab,2019,104:2527-2534.
|
| [10] |
Beccuti G, Guaraldi F, Natta G, et al. Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study[J]. J Endocrinol Invest, 2021,44:1699-1706.
|
| [11] |
De Sousa SMC, Baranoff J, Rushworth RL, et al. Impulse control disorders in dopamine agonist-treated hyperprolactinemia: prevalence and risk factors[J]. J Clin Endocrinol Metab,2020,105. doi: 10.1210/clinem/dgz076.
|
| [12] |
Ozkaya HM, Sahin S, Korkmaz OP, et al. Patients with acromegaly might not be at higher risk for dopamine agonist-induced impulse control disorders than those with prolactinomas[J]. Growth Horm IGF Res,2020,55:101356. doi: 10.1016/j.ghir.2020.101356.
|
| [13] |
Kon T, Ueno T, Haga R, et al. The factors associated with impulse control behaviors in Parkinson's disease: a 2-year longitudinal retrospective cohort study[J]. Brain Behav,2018,8:e01036. doi: 10.1002/brb3.1036.
|
| [14] |
Fantini ML, Figorilli M, Arnulf I, et al. Sleep and REM sleep behaviour disorder in Parkinson's disease with impulse control disorder[J]. J Neurol Neurosurg Psychiatry,2018,89:305-310.
|
| [15] |
Corvol JC, Artaud F, Cormier-Dequaire F, et al. Longitudinal analysis of impulse control disorders in Parkinson disease[J]. Neurology,2018,91:e189-e201. doi: 10.1212/wnl.0000000000005816.
|
| [16] |
Bastiaens J, Dorfman BJ, Christos PJ, et al. Prospective cohort study of impulse control disorders in Parkinson's disease[J]. Mov Disord,2013,28:327-333.
|
| [17] |
Martinez-Martin P, Wan YM, Ray Chaudhuri K, et al. Impulse control and related behaviors in Parkinson's disease with dementia[J]. Eur J Neurol,2020,27:944-950.
|
| [18] |
Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society Clinical Practice Guideline[J]. J Clin Endocrinol Metab,2011,96:273-288.
|
| [19] |
Matsuda N, Kobayashi S, Ugawa Y. Devotion to painting in a Parkinson's disease patient[J]. Rinsho Shinkeigaku,2018,58:756-760.
|
| [20] |
Seeman P. Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors[J]. Synapse,2015,69:183-189.
|
| [21] |
Wolfschlag M, Hkansson A. Increased risk for develop-ing gambling disorder under the treatment with prami-pexole, ropinirole, and aripiprazole: a nationwide register study in Sweden[J]. PLoS One, 2021,16:e0252516. doi: 10.1371/journal.pone.0252516.
|
| [22] |
Gallagher DA, O'Sullivan SS, Evans AH, et al. Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series[J]. Mov Disord,2007,22:1757-1763.
|
| [23] |
Ioachimescu AG, Fleseriu M, Hoffman AR, et al. Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas[J]. Eur J Endocrinol,2019,180:31-40.
|
| [24] |
Allard L, Albarel F, Bertherat J, et al. Efficacy and safety of dopamine agonists in patients treated with antipsychotics and presenting a macroprolactinoma[J]. Eur J Endocrinol, 2020,183:221-231.
|
| [25] |
Lee JY, Jeon B, Koh SB, et al. Behavioural and trait changes in parkinsonian patients with impulse control disorder after switching from dopamine agonist to levodopa therapy: results of REIN-PD trial[J]. J Neurol Neurosurg Psychiatry,2019,90:30-37.
|
| [26] |
Kim A, Kim YE, Kim HJ, et al. A 7-year observation of the effect of subthalamic deep brain stimulation on impulse control disorder in patients with Parkinson's disease[J]. Parkinsonism Relat Disord, 2018,56:3-8.
|
| [27] |
Rodríguez-Violante M, Ríos-Solís Y, Esquivel-Zapata O, et al. Assessment of therapeutic strategies for management of impulse control disorder in Parkinson's disease[J]. Arq Neuropsiquiatr, 2021,79:989-994.
|
| [28] |
De Sousa SM, Chapman IM, Falhammar H, et al. Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists[J]. Endocrine, 2017,55:618-624.
|
